Utilities for asthma and COPD according to category of severity: A comprehensive literature review

Journal of Medical Economics

Volumn 18, Issue 7, 2015, Pages 550-563

  Einarson, Thomas R ^a   Bereza, Basil G ^a   Nielsen, T Anders ^b   Hemels, Michiel E H ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Janssen Pharma A/S   (Denmark)

Author keywords

Asthma; COPD; Preferences; Severe; Utilities

Indexed keywords

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; COST UTILITY ANALYSIS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; SYSTEMATIC REVIEW; COST; PATHOPHYSIOLOGY; PSYCHOLOGY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ASTHMA; COSTS AND COST ANALYSIS; HUMANS; MODELS, ECONOMETRIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84942786026     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1025793     Document Type: Article

References (121)

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380: 2163-96
2. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012;12:204
3. Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc 2014;11:404-6
4. Abramson MJ, Perret JL, Dharmage SC, et al. Distinguishing adult-onset asthma from COPD: a review and a new approach. Int J Chron Obstruct Pulmon Dis 2014;9:945-62
5. Wechsler ME. Getting control of uncontrolled asthma. Am J Med 2014 Nov; 127:1049-59
6. CDC National surveillance of asthma: United States. Vital Health and Statistics Series 3 Number
7. US Department of Health and Human Services, 2012. Washington, DC, http://www.cdc.gov/nchs/data/series/sr-03/sr03-035.pdf. Accessed Dec. 9, 2014
8. Global Initiative for Chronic Obstructive Lung Disease. Pocket guide to COPD diagnosis, management and prevention. 2011. Global Initiative for Chronic Obstructive Lung Disease Inc., Bethesda, MD, http://www.goldcopd.org/uploads/users/files/GOLD-Pocket-May2512.pdf. Accessed Dec. 9, 2014
9. World Health Organization. Top 10 leading causes of death in the world 2012. Geneva, http://www.who.int/mediacentre/factsheets/fs310/en/2012. Accessed Dec. 9, 2014
10. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2010. Global Initiative for Asthma, Bethesda, MD, www. ginasthma.org/pdf/GINA-report-2010.pdf. Accessed Dec. 9, 2014
11. Calhoun WJ, Haselkorn T, Mink DR, et al. Clinical burden and predictors of asthma exacerbations in patients on guideline-based steps 4-6 asthma therapy in the TENOR cohort. J Allergy Clin Immunol Pract 2014;2: 193-200
12. O'Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2014;Jun 10:pii: thoraxjnl-2013-204114
13. Punekar YS, Wurst K, Shukla A. Resource use and costs up to two years post diagnosis among newly diagnosed COPD patients in the UK primary care setting: a retrospective cohort study. COPD 2014;Aug 5:[Epub ahead of print]
14. Serra-Batlles J, Plaza V, Morejon E, et al. Costs of asthma according to the degree of severity. Eur Respir J 1998;12:1322-6
15. Gonzalez-Barcala FJ, de la Fuente-Cid R, Tafalla M, et al. Factors associated with health-related quality of life in adults with asthma. A cross-sectional study. Multidiscip Respir Med 2012;7:32
16. Al-kalemji A, Petersen KD, Sørensen J, et al. Factors influencing quality of life in asthmatics-a case-control study. Clin Respir J 2013;7:288-96
17. Solem CT, Sun SX, Sudharshan L, et al. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013;8:641-52
18. Luskin AT, Chipps BE, Rasouliyan L, et al. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract 2014;2:544-52
19. Correia de Sousa J, Pina A, Cruz AM, et al. Asthma control, quality of life, and the role of patient enablement: a cross-sectional observational study. Prim Care Respir J 2013;22:181-7
20. Weldam SW, Lammers JW, Heijmans MJ, et al. Perceived quality of life in chronic obstructive pulmonary disease patients: a cross-sectional study in primary care on the role of illness perceptions. BMC Fam Pract 2014;14:140
21. Paterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res 2000;9:521-7
22. Starkie HJ, Briggs AH, Chambers MG, et al. Predicting EQ-5D values using the SGRQ. Value Health 2011;14:354-60
23. Gani R, Griffin J, Kelly S, et al. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010;19:68-74
24. Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006;130: 1117-28
25. Sun SX, Marynchenko M, Banerjee R, et al. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Econ 2011;14:805-15
26. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005;23: 619-37
27. Al MJ, Koopmanschap MA, van Enckevort PJ, et al. Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis. Chest 1998;113: 124-30
28. Chen J, Wong CK, McGhee SM, et al. A comparison between the EQ-5D and the SF-6D in patients with chronic obstructive pulmonary disease (COPD). PLoS One 2014;9:e112389
29. Hajizadeh N, Crothers K, Braithwaite RS. Informing shared decisions about advance directives for patients with severe chronic obstructive pulmonary disease: a modeling approach. Value Health 2012;15:357-66
30. Jodar-Sanchez F, Ortega F, Parra C, et al. Implementation of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy. J Telemed Telecare 2013;19:11-17
31. Kim SH, Oh YM, Jo MW. Health-related quality of life in chronic obstructive pulmonary disease patients in Korea. Health Qual Life Outcomes 2014;12:57
32. Lin FJ, Pickard AS, Krishnan JA, et al. Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form. BMC Med Res Methodol 2014;14:78
33. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations-comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes 2010;8:39.
34. Miravitlles M, Huerta A, Fernandez-Villar JA, et al. Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems. Health Qual Life Outcomes 2014;12:120.
35. Pickard AS, Yang Y, Lee TA. Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. Health Qual Life Outcomes 2011;9:26
36. Rutten-van Mölken MP, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics 2009;27:465-77
37. Schünemann HJ, Norman G, Puhan MA, et al. Application of generalizability theory confirmed lower reliability of the standard gamble than the feeling thermometer. J Clin Epidemiol 2007;60:1256-62
38. Stahl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005;3:56
39. Szende A, Leidy NK, Stahl E, et al. Estimating health utilities in patients with asthma and COPD: Evidence on the performance of EQ-5D and SF-6D. Qual Life Res 2009;18:267-72
40. Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004;7:153-67
41. Goossens LM, Nivens MC, Sachs P, et al. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respir Med 2011;105:1195-202
42. Jodar-Sanchez F, Ortega F, Parra C, et al. Cost-utility analysis of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy. J Telemed Telecare 2014;20:307-16
43. Oostenbrink JB, Rutten-van Mölken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005;8:32-46
44. Atsou K, Chouaid C, Hejblum G. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. PLoS One 2011;6:e24870
45. Chandra K, Blackhouse G, McCurdy BR, et al. Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model. Ont Health Technol Assess Ser 2012;12:1-61. http://www.hqontarioca/en/mas/tech/pdfs/2012rev-COPD-Economic-Marchpdf. Accessed Dec. 9, 2014
46. Chuck A, Jacobs P, Mayers I, et al. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease. Can Respir J 2008;15: 437-43
47. Earnshaw SR, Wilson MR, Dalal AA, et al. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med 2009;103:12-21
48. Hertel N, Kotchie RW, Samyshkin Y, et al. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J COPD 2012;7:183-99
49. Hettle R, Wouters H, Ayres J, et al. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respir Med 2012;106:1722-33
50. Hoogendoorn M, Al MJ, Beeh KM, et al. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Eur Respir J 2013;41: 556-64
51. Hoogendoorn M, Rutten-van Mölken MPHM, Hoogenveen RT, et al. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health 2011;14:1039-47
52. Hoogendoorn M, Feenstra TL, Hoogenveen RT, et al. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 2010;65:711-18
53. Lock K, Wilson K, Murphy D, et al. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother 2011;12:2613-26
54. Maniadakis N, Tzanakis N, Fragoulakis V, et al. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr Med Res Opin 2006;22: 1599-607
55. Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics 2012;30: 825-40
56. Miller JD, Malthaner RA, Goldsmith CH, et al. A randomized clinical trial of lung volume reduction surgery versus best medical care for patients with advanced emphysema: a two-year study from Canada. Ann Thorac Surg 2006;81:314-20
57. Milne RJ, Hockey H, Rea H. Long-term air humidification therapy is costeffective for patients with moderate or severe chronic obstructive pulmonary disease or bronchiectasis. Value Health 2014;17:320-7
58. Oostenbrink JB, Al MJ, Oppe M, et al. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health 2008;11:1070-80
59. Price D, Asukai Y, Ananthapavan J, et al. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use. Appl Health Econ Health Policy 2013;11:259-74
60. Price D, Keininger D, Costa-Scharplatz M, et al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir Med 2014;108:1786-93
61. Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011;105:1635-47
62. Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007;8:123-35
63. Samyshkin Y, Kotchie R, Mörk A-C, et al. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. Eur J Health Econ 2014;15:69-82
64. Samyshkin Y, Schlunegger M, Haefliger S, et al. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Int J Chron Obstruct Pulmon Dis 2013;8:79-87
65. McTaggart-Cowan HM, Marra CA, Yang Y, et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Qual Life Res 2008;17:453-62
66. Bime C, Wei CY, Holbrook JT, et al. Asthma symptom utility index: reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. J Allergy Clin Immunol 2012;130:1078-84
67. Flood EM, De Cock E, Mörk AC, et al. Evaluating preference weights for the Asthma Symptom Utility Index (ASUI) across countries. Health Qual Life Outcomes 2006;15:4:51
68. Carroll AE, Downs SM. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr 2009;155:21-5, 25.e1-5
69. Finnell SME, Carroll AE, Downs SM. Application of classic utilities to published pediatric cost-utility studies. Acad Pediatr 2012;12:219-28
70. Chen H, Gould MK, Blanc PD, et al. Asthma control, severity, and quality of life: Quantifying the effect of uncontrolled disease. J Allergy Clin Immunol 2007;120:396-402
71. Szende A, Svensson K, Stahl E, et al. Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. Pharmacoeconomics 2004;22:537-47
72. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998;114:998-1007
73. Lloyd A, Doyle S, Dewilde S, et al. Preferences and utilities for the symptoms of moderate to severe allergic asthma. Eur J Health Econ 2008;9:275-84
74. McCallister JW, Holbrook JT, Wei CY, et al. Sex differences in asthma symptom profiles and control in the American Lung Association Asthma Clinical Research Centers. Respir Med 2013;107:1491-500
75. Brusselle G, Michils A, Louis R, et al. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009;103:1633-42
76. Rutten-van Molken MP, Custers F, van Doorslaer EK, et al. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J 1995;8:888-98
77. Brown R, Turk F, Dale P, et al. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62:149-53
78. Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010;65:1141-8
79. Dal Negro RW, Pradelli L, Tognella S, et al. Cost-utility of add-on Omalizumab in difficult-totreat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011;43:45-53
80. Dewilde S, Turk F, Tambour M, et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: Adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:1765-76
81. Gerzeli S, Rognoni C, Quaglini S, et al. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. Clin Drug Investig 2012; 32:253-65
82. Nahon-Levy A, Garc?a ARJ, Garc?a-Agua NS, et al. Cost-effectiveness of omalizumab in severe persistent asthma in spain: a real-life perspective. J Asthma 2014;24:1-6
83. Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in Japan and the value of responder prediction methods based on a multinational trial. Value Health 2013;2: 29-36
84. Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess 2013;17:1-342
85. Plaza V, Serra-Batlles J, Ferrer M, et al. Quality of life and economic features in elderly asthmatics. Respiration 2000;67:65-70
86. Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy 2009;64:431-8
87. van Nooten F, Stern S, Braunstahl GJ, et al. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ 2013; 16:342-8
88. Willson J, Bateman ED, Pavord I, et al. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting b-agonists. Appl Health Econ Health Policy 2014;12: 447-59
89. Moy ML, Fuhlbrigge AL, Blumenschein K, et al. Association between preference-based health-related quality of life and asthma severity. Ann Allergy Asthma Immunol 2004;92:329-34
90. Zahran HS, Bailey CM, Qin X, et al. Assessing asthma severity among children and adults with current asthma. J Asthma 2014;51:610-17
91. Dankner R, Olmer L, Ziv A, et al. A simplified severity score for acute asthma exacerbation. J Asthma 2013;50:871-6
92. Global Initiative for Asthma. Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS). Secondary Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS). 2014. Global Initiative for Asthma, Bethesda, MD, http://www.ginasthma.org/local/uploads/files/AsthmaCOPDOverlap.pdf. Accessed Dec. 9, 2014
93. Global Initiative for Chronic Lung Disease. GOLD Report. Secondary GOLD Report. 2014. Global Initiative for Chronic Obstructive Lung Disease Inc., Bethesda, MD, http://www.goldcopd.org/uploads/users/files/GOLD-Report-2014-Jan23.pdf. Accessed Dec. 9, 2014
94. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009;64:728-35
95. O'Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007;61:1112-20
96. Partridge MR, Dal Negro RW, Olivieri D. Understanding patients with asthma and COPD: insights from a European study. Prim Care Respir J 2011;20:315-23
97. Goossens LM, Baker CL, Monz BU, et al. Adjusting for COPD severity in database research: developing and validating an algorithm. Int J COPD 2011;6:669-78
98. McTaggart-Cowan HM, Shi P, FitzGerald JM, et al. An evaluation of patients' willingness to trade symptom-free days for asthma related treatment risks: a discrete choice experiment. J Asthma 2008;45:630-8
99. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on healthrelated quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007;16:22-7
100. Szende A, Svensson K, Stahl E, et al. Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. Pharmacoeconomics 2004;22:537-47
101. Spencer S, Jones PW; Globe Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589-93
102. Brazier J, Spencer MD, Zhu J. Exacerbations during a 6-month trial and health status at endpoint. Abstract P1605. Presented at the 12th Annual Congress of the European Respiratory Society, Stockholm, 2002. European Respiratory Society 2002, pp. 14-18
103. Al MJ, Koopmanschap MA, van Enckevort PJ, et al. Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis. Chest 1998;113:124-30
104. Soler-Cataluna JJ, Mart?nez-Garc?a MA, Roman-Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31
105. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:700-8
106. Calverly PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94
107. Asukai Y, Baldwin M, Mungapen L. Utility values for COPD patients based on the EQ-5D questionnaire from three indacaterol Phase III studies. Abstract P84. Thorax 2012;67(2 Suppl):A100-1
108. Price D, Lee AJ, Sims E, et al. Preference for once-daily inhaler therapy and its correlates in community managed patients with asthma and COPD. Am J Respir Crit Care Med 2011;183 (1 Meeting Abstracts)
109. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62
110. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twicedaily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273-9
111. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004;1:303-12
112. Prescott-Clarke P, Primatesta P. Health survey for England 1996. London: HMSO, 1998
113. Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of antiimmunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. ETOPA Trial. Allergy 2004;59:701-8
114. Price D, Brown RE, Lloyd A. Burden of poorly controlled asthma for patients and society in the UK. Prim Care Resp J 2004;13:113-14
115. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
116. Allegra L, Cremonesi G, Girbino G, et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. PRISMA (PRospectIve Study on asthMA control) Study Group. Respir Med 2012; 106:205-14
117. Briggs AH, Bousquet J, Wallace MV, et al. Investigators Group. Costeffectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006;61:531-6
118. Edelen MO, Burnam MA, Watkins KE, et al. Obtaining utility estimates of the health value of commonly prescribed treatments for asthma and depression. Med Decis Making 2008;28:732-50
119. Steuten L, Palmer S, Vrijhoef B, et al. Cost-utility of a disease management program for patients with asthma. Int J Technol Assess Health Care 2007;23:184-91
120. Bousquet J, Siergiejko Z, Swiebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. EXALT TRIAL. Allergy 2011;66:671-8
121. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. PrimoTinA asthma trials. N Engl J Med 2012;367:1198-207